Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO2017139336) METHOD OF PREVENTING AND TREATING RETINAL MICROVASCULATURE INFLAMMATION USING C-MET SIGNALING PATHWAY INHIBITION
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2017/139336 International Application No.: PCT/US2017/016945
Publication Date: 17.08.2017 International Filing Date: 08.02.2017
IPC:
A61K 39/395 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
Applicants:
TIRGAN, Nima [US/US]; US
Inventors:
TIRGAN, Nima; US
Agent:
ACKER WOOD, Gwen; US
Priority Data:
15/019,00009.02.2016US
15/407,54317.01.2017US
Title (EN) METHOD OF PREVENTING AND TREATING RETINAL MICROVASCULATURE INFLAMMATION USING C-MET SIGNALING PATHWAY INHIBITION
(FR) PROCÉDÉ DE PRÉVENTION ET DE TRAITEMENT D’UNE INFLAMMATION DE LA MICROVASCULARISATION RÉTINIENNE AU MOYEN DE L’INHIBITION DE LA VOIE DE SIGNALISATION C-MET
Abstract:
(EN) The present invention provides methods for preventing retinal microvasculature inflammation in patients with diabetes who are highly susceptible to developing diabetic retinopathy and/or diabetic macular edema. The methods comprise inhibiting C-met signaling pathway by administering a C-met inhibitor alone or in combination with anti-VEGF or steroid medications to diabetic patients. The methods thus provide a surprisingly effective prophylaxis and/or treatment for diabetic retinopathy and/or diabetic macular edema.
(FR) La présente invention concerne des procédés de prévention d’une inflammation de la microvascularisation rétinienne chez des patients atteints de diabète qui sont hautement susceptibles de développer une rétinopathie diabétique et/ou un œdème maculaire diabétique. Les procédés comprennent l’inhibition de la voie de signalisation C-met par administration d’un inhibiteur de C-met seul ou en combinaison avec des médicaments anti-VEGF ou stéroïdiens à des patients diabétiques. Les procédés permettent ainsi une prophylaxie et/ou un traitement étonnamment efficace pour la rétinopathie diabétique et/ou l’œdème maculaire diabétique.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)